Health Care

Genmab’s Phase 3 EPCORE DLBCL‑4 trial shows epcoritamab + lenalidomide cuts progression risk by ~60 % in relapsed/refractory DLBCL, with a manageable safety profile and potential for broader use.

Pro Medic Ltd. attracts tech‑savvy investors and clinical users alike—its diagnostics software boosts accuracy, safety, and workflow while driving strong ASX momentum.

Elevance Health (ELV) completes a $4.80‑exercise‑price, cash‑free tranche of 5 + million options, expanding equity while keeping its capital base steady.

AbbVie’s Phase‑3 epcoritamab + lenalidomide study shows a clear PFS win in relapsed/refractory DLBCL, offering a safe, fixed‑duration, cost‑effective alternative to CAR‑T and chemo‑immunotherapy.

Explore how Bayer’s share decline reflects legal risks and its life‑science strategy, from oncology breakthroughs to glyphosate litigation impacts.

Merck’s $11 B cash takeover of Bio‑Techne fuels a surge in U.S. healthcare equity, revealing how strategic M&A, cost‑efficiency, and patient access shape tomorrow’s pharma landscape.

UnitedHealth Group’s Q2 earnings outlook shows a 5‑7 pp Medicare Advantage margin boost, $80 M PPO savings, and AI‑driven OptumHealth gains—boosting net earnings while navigating PBM risk.

Johnson & Johnson’s latest trading session shows modest gains amid cautious optimism. Explore how portfolio diversification, patent cliffs, and strategic M&A drive J&J’s growth prospects.

Fresenius Medical Care AG shares its 2025 401(k) audit, a 2‑million share buyback, and market outlook, highlighting strong employee benefits and shareholder value creation.

Danaher’s decade‑long share‑price surge (+112%) proves long‑term investor value, while its $1 M Ebola aid showcases how corporate expertise fuels global health impact.